Dingdang Health Technology Group Ltd. (abbrev. Dingdang Health) filed a Next Day Disclosure Return on 16 April 2026, confirming further progress under its on-market share repurchase programme.

Key points • Issued share capital remained unchanged at 1.32 billion ordinary shares as of 15 April 2026. • On 16 April 2026 the company repurchased 0.17 million shares on the Hong Kong Stock Exchange at HKD 1.05–1.06 per share, for a total consideration of HKD 0.18 million. • Including this transaction, 41.93 million shares bought back since 25 November 2025 are still awaiting cancellation. This volume represents 3.18 % of the company’s issued shares when the current mandate was approved on 28 May 2025. • The board is authorised to repurchase up to 131.95 million shares; utilisation now stands at 31.8 %. • In accordance with Hong Kong listing rules, Dingdang Health is subject to a moratorium on new share issues or treasury-share sales until 16 May 2026.

All buybacks were executed in compliance with the Main Board Listing Rules and the terms of the explanatory statement dated 30 April 2025.